A comprehensive and practical approach to the management of idiopathic pulmonary fibrosis

References

• Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.
   PubMed Web of Science ®Google Scholar
• Nicholson AG, Colby TV, Du Bois RM, et al. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med. 2000;162(6):2213–2217.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Toews GB, Travis WD, et al. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J. 2002;19(2):275–283.
   PubMed Web of Science ®Google Scholar
• Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431–440.
   PubMed Web of Science ®Google Scholar
• Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis. 2008;3:8.
   PubMed Web of Science ®Google Scholar
• Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(7):810–816.
   PubMed Web of Science ®Google Scholar
• Daccord C, Maher TM. Recent advances in understanding idiopathic pulmonary fibrosis. F1000Res. 2016;5:1046. eCollection 2016.
   PubMedGoogle Scholar
• Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176(7):636–643.
   PubMed Web of Science ®Google Scholar
• Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. an international working group report. Am J Respir Crit Care Med. 2016;194(3):265–275.
   PubMed Web of Science ®Google Scholar
• Collard HR, King TE Jr, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168(5):538–542.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168(5):543–548.
   PubMed Web of Science ®Google Scholar
• Durheim MT, Collard HR, Roberts RS, et al. Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Lancet Respir Med. 2015;3(5):388–396.
   PubMed Web of Science ®Google Scholar
• Paterniti MO, Bi Y, Rekic D, et al. Acute exacerbation and decline in forced vital capacity are associated with increased mortality in idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2017;14(9):1395–1402.
   PubMed Web of Science ®Google Scholar
• Hook JL, Arcasoy SM, Zemmel D, et al. Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis. Eur Respir J. 2012;39(2):359–365.
   PubMed Web of Science ®Google Scholar
• Raghu G, Richeldi L. Current approaches to the management of idiopathic pulmonary fibrosis. Respir Med. 2017;129:24–30.
   PubMed Web of Science ®Google Scholar
• Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378(19):1811–1823.
   PubMed Web of Science ®Google Scholar
• Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44–e68.
   PubMed Web of Science ®Google Scholar
• Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3–e19.
   PubMed Web of Science ®Google Scholar
• Akhtar AA, Ali MA, Smith RP. Depression in patients with idiopathic pulmonary fibrosis. Chron Respir Dis. 2013;10(3):127–133.
   PubMed Web of Science ®Google Scholar
• Ryerson CJ, Arean PA, Berkeley J, et al. Depression is a common and chronic comorbidity in patients with interstitial lung disease. Respirology. 2012;17(3):525–532.
   PubMed Web of Science ®Google Scholar
• Kulkarni T, Willoughby J, Acosta Lara M, et al. A bundled care approach to patients with idiopathic pulmonary fibrosis improves transplant-free survival. Respir Med. 2016;115:33–38.
   PubMed Web of Science ®Google Scholar
• Kalluri M, Claveria F, Ainsley E, et al. Beyond idiopathic pulmonary fibrosis diagnosis: multidisciplinary care with an early integrated palliative approach is associated with a decrease in acute care utilization and hospital deaths. J Pain Symptom Manage. 2018;55(2):420–426.
   PubMed Web of Science ®Google Scholar
• Pooler C, Richman-Eisenstat J, Kalluri M. Early integrated palliative approach for idiopathic pulmonary fibrosis: a narrative study of bereaved caregivers’ experiences. Palliat Med. 2018;32(9):1455–1464.
   Web of Science ®Google Scholar
• Holland AE, Fiore JF Jr, Goh N, et al. Be honest and help me prepare for the future: what people with interstitial lung disease want from education in pulmonary rehabilitation. Chron Respir Dis. 2015;12(2):93–101.
   PubMed Web of Science ®Google Scholar
• van Manen MJG, van ‘t Spijker A, Tak NC, et al. Patient and partner empowerment programme for idiopathic pulmonary fibrosis. Eur Respir J. 2017;49(4):1601596.
   PubMed Web of Science ®Google Scholar
• Senanayake S, Harrison K, Lewis M, et al. Patients’ experiences of coping with idiopathic pulmonary fibrosis and their recommendations for its clinical management. PLoS One. 2018;13(5):e0197660.
   PubMed Web of Science ®Google Scholar
• Fisher JH, O’Connor D, Flexman AM, et al. Accuracy and reliability of internet resources for information on idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2016;194(2):218–225.
   PubMed Web of Science ®Google Scholar
• Sampson C, Gill BH, Harrison NK, et al. The care needs of patients with idiopathic pulmonary fibrosis and their carers (CaNoPy): results of a qualitative study. BMC Pulm Med. 2015;15: 155.
   PubMed Web of Science ®Google Scholar
• Overgaard D, Kaldan G, Marsaa K, et al. The lived experience with idiopathic pulmonary fibrosis: a qualitative study. Eur Respir J. 2016;47(5):1472–1480.
   PubMed Web of Science ®Google Scholar
• Bajwah S, Higginson IJ, Ross JR, et al. The palliative care needs for fibrotic interstitial lung disease: a qualitative study of patients, informal caregivers and health professionals. Palliat Med. 2013;27(9):869–876.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE 2018). Idiopathic pulmonary fibrosis in adults: diagnosis and management (clinical guideline). London, UK: NICE; 2018.
   Google Scholar
• Duck A, Pigram L, Errhalt P, et al. IPF care: a support program for patients with idiopathic pulmonary fibrosis treated with pirfenidone in europe. Adv Ther. 2015;32(2):87–107.
   PubMed Web of Science ®Google Scholar
• Chaudhuri N, Duck A, Frank R, et al. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis. Respir Med. 2014;108(1):224–226.
   PubMed Web of Science ®Google Scholar
• King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–2092.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079–1087.
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–1769.
   PubMed Web of Science ®Google Scholar
• Nathan SD, Albera C, Bradford WZ, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2017;5(1):33–41.
   PubMed Web of Science ®Google Scholar
• Ley B, Swigris J, Day BM, et al. Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2017;196(6):756–761.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Cottin V, Du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS® trials. Respir Med. 2016;113:74–79.
   PubMed Web of Science ®Google Scholar
• Costabel U, Albera C, Lancaster LH, et al. An open-label study of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (RECAP). Respiration. 2017;94(5):408–415.
   PubMed Web of Science ®Google Scholar
• Crestani B, Huggins JT, Kaye M, et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2019;7(1):60-68.
   PubMed Web of Science ®Google Scholar
• Albera C, Costabel U, Fagan EA, et al. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J. 2016;48(3):843–851.
   PubMed Web of Science ®Google Scholar
• Kolb M, Richeldi L, Behr J, et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax. 2017;72(4):340–346.
   PubMed Web of Science ®Google Scholar
• Wuyts WA, Kolb M, Stowasser S, et al. First data on efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and forced vital capacity of ≤50% of predicted value. Lung. 2016;194(5):739–743.
   PubMed Web of Science ®Google Scholar
• Costabel U, Albera C, Glassberg MK, et al. Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis. Respir Res. 2019;20(1): 55.
   PubMedGoogle Scholar
• Tzouvelekis A, Ntolios P, Karampitsakos T, et al. Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis: a real-world observational study. Pulm Pharmacol Ther. 2017;46:48–53.
   PubMed Web of Science ®Google Scholar
• Harari S, Caminati A, Poletti V, et al. A real-life multicenter national study on nintedanib in severe idiopathic pulmonary fibrosis. Respiration. 2018;95(6):433–440.
   PubMed Web of Science ®Google Scholar
• Nathan SD, Albera C, Bradford WZ, et al. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax. 2016;71(5):429–435.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Kolb M, Azuma A, et al. FVC decline over 1 year predicts mortality but not subsequent FVC decline in patients with IPF. Eur Respir J. 2017;50(suppl 61):PA4892.
   Web of Science ®Google Scholar
• Esbriet (pirfenidone) [monograph]. Mississauga, ON, Canada: F. Hoffmann-La Roche Ltd.; 2018.
   Google Scholar
• Esbriet (pirfenidone) capsules and film-coated tablets, for oral use [package insert]. South San Francisco, CA: Genentech, Inc.; 2017.
   Google Scholar
• Esbriet (pirfenidone) capsules and film-coated tablets, for oral use [summary of product characteristics]. Grenzach-Wyhlen, Germany: Roche Registration GmbH; 2017.
   Google Scholar
• Ofev (nintedanib) [monograph]. Burlington, ON, Canada: Boehringer Ingelheim (Canada) Ltd..
   Google Scholar
• Boehringer Ingelheim. Ofev (nintedanib) capsules, for oral use [package insert]. Ridgefield, CT; 2018.
   Google Scholar
• Ofev (nintedanib) capsules, for oral use [summary of product characteristics] Ingelheim am Rhein, Germany: Boehringer Ingelheim International GmbH; 2018.
   Google Scholar
• Glassberg MK, Nathan SD, Lin CY, et al. Cardiovascular events in phase 3 trials of pirfenidone in idiopathic pulmonary fibrosis (IPF). Am J Respir Crit Care Med. 2016;193:A4980.
   Google Scholar
• Noth I, Wijsenbeek M, Kolb M, et al. Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials. Am J Respir Crit Care Med. 2017;195:A5383.
   Web of Science ®Google Scholar
• Pan L, Belloni P, Ding HT, et al. A pharmacokinetic bioequivalence study comparing pirfenidone tablet and capsule dosage forms in healthy adult volunteers. Adv Ther. 2017;34(9):2071–2082.
   PubMed Web of Science ®Google Scholar
• King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378(9807):1949–1961.
   PubMed Web of Science ®Google Scholar
• Kondoh Y, Taniguchi H, Katsuta T, et al. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27(2):103–110.
   PubMed Web of Science ®Google Scholar
• Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011;37(2):356–363.
   PubMed Web of Science ®Google Scholar
• Lancaster L, Morrison L, Auais A, et al. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis in a US expanded access program. Am J Respir Crit Care Med. 2016;193:A2695.
   Google Scholar
• Lancaster LH, de Andrade JA, Zibrak JD, et al. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. Eur Respir Rev. 2017;26(146):170057.
   PubMed Web of Science ®Google Scholar
• Cottin V. The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis. Expert Opin Drug Saf. 2017;16(7):857–865.
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016;47(1):243–253.
   PubMed Web of Science ®Google Scholar
• Mason WR, Nathan SD, Zibrak JD, et al. Time-to-event analysis of common adverse events with pirfenidone in patients with IPF—a pooled analysis of three phase III clinical trials. Am J Respir Crit Care Med. 2017;195:A6798.
   Google Scholar
• Hughes G, Toellner H, Morris H, et al. Real world experiences: pirfenidone and nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis. J Clin Med. 2016;5(9):78.
   PubMed Web of Science ®Google Scholar
• Galli JA, Pandya A, Vega-Olivo M, et al. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: tolerability and adverse drug reactions. Respirology. 2017;22(6):1171–1178.
   PubMed Web of Science ®Google Scholar
• Costabel U, Bendstrup E, Cottin V, et al. Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther. 2014;31(4):375–391.
   PubMed Web of Science ®Google Scholar
• Corte T, Bonella F, Crestani B, et al. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res. 2015;16: 116-015-0276-5.
   PubMed Web of Science ®Google Scholar
• Cottin V, Maher T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev. 2015;24(135):58–64.
   PubMed Web of Science ®Google Scholar
• Cottin V, Koschel D, Günther A, et al. Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study. ERJ Open Res. 2018;4(4):00084–2018.
   Google Scholar
• Lancaster LH, Morrison L, Auais A, et al. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: experience from 92 sites in an open-label US expanded access program. Pulm Ther. 2017;3:317.
   Google Scholar
• Nathan SD, Lancaster LH, Albera C, et al. Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials. BMJ Open Respir Res. 2018;5(1):e000323.
   PubMed Web of Science ®Google Scholar
• Maher TM, Inoue Y, Case AH, et al. Effect of dose reductions and/or interruptions on the efficacy of nintedanib in patients with idiopathic pulmonary fibrosis (IPF): subgroup analysis of the INPULSIS trials. Am J Respir Crit Care Med. 2017;195:A5381.
   Web of Science ®Google Scholar
• Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014—an update from the pulmonary transplantation council of the international society for heart and lung transplantation. J Heart Lung Transplant. 2015;34(1):1–15.
   PubMed Web of Science ®Google Scholar
• Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J. 2006;27(1):136–142.
   PubMed Web of Science ®Google Scholar
• Tobin RW, Pope CE 2nd, Pellegrini CA, et al. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;158(6):1804–1808.
   PubMed Web of Science ®Google Scholar
• Lee JS, Ryu JH, Elicker BM, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(12):1390–1394.
   PubMed Web of Science ®Google Scholar
• Ghebre YT, Raghu G. Idiopathic pulmonary fibrosis: novel concepts of proton pump inhibitors as antifibrotic drugs. Am J Respir Crit Care Med. 2016;193(12):1345–1352.
   PubMed Web of Science ®Google Scholar
• Johannson KA, Strambu I, Ravaglia C, et al. Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? Lancet Respir Med. 2017;5(7):591–598.
   PubMed Web of Science ®Google Scholar
• Kreuter M, Spagnolo P, Wuyts W, et al. Antacid therapy and disease progression in patients with idiopathic pulmonary fibrosis who received pirfenidone. Respiration. 2017;93(6):415–423.
   PubMed Web of Science ®Google Scholar
• Costabel U, Behr J, Crestani B, et al. Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS trials. Respir Res. 2018;19(1): 167.
   Google Scholar
• Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med. 2013;1(5):369–376.
   PubMed Web of Science ®Google Scholar
• Fidler L, Sitzer N, Shapera S, et al. Treatment of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Chest. 2018;153(6):1405–1415.
   PubMed Web of Science ®Google Scholar
• Tran T, Suissa S. The effect of anti-acid therapy on survival in idiopathic pulmonary fibrosis: a methodological review of observational studies. Eur Respir J. 2018;51(6):1800376.
   PubMed Web of Science ®Google Scholar
• Dutta P, Funston W, Mossop H, et al. Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis. Thorax. 2019;74(4):346–353.
   PubMed Web of Science ®Google Scholar
• Raghu G, Pellegrini C, Yow ES, et al. A phase 2 randomized, controlled trial of laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2018;197:A7698.
   Google Scholar
• Lancaster LH, Mason WR, Parnell JA, et al. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest. 2009;136(3):772–778.
   PubMed Web of Science ®Google Scholar
• Mermigkis C, Bouloukaki I, Antoniou K, et al. Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis. Sleep Breath. 2015;19(1):385–391.
   PubMed Web of Science ®Google Scholar
• Cottin V. The impact of emphysema in pulmonary fibrosis. Eur Respir Rev. 2013;22(128):153–157.
   PubMedGoogle Scholar
• Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006;129(3):746–752.
   PubMed Web of Science ®Google Scholar
• Alyami S, Yang R, Moran-Mendoza O. Idiopathic pulmonary fibrosis management review. SM J Biomed Eng. 2017;3(1):1018.
   Google Scholar
• Kolb M, Raghu G, Wells AU, et al. Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2018;379(18):1722–1731.
   PubMed Web of Science ®Google Scholar
• Behr J, Nathan SD, Harari S, et al. Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a phase IIb, randomised, double-blind, placebo-controlled study - rationale and study design. Respir Med. 2018;138:13–20.
   PubMed Web of Science ®Google Scholar
• Hubbard R, Venn A, Lewis S, et al. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med. 2000;161(1):5–8.
   PubMed Web of Science ®Google Scholar
• Le Jeune I, Gribbin J, West J, et al. The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med. 2007;101(12):2534–2540.
   PubMed Web of Science ®Google Scholar
• Bargagli E, Bonti V, Ferrari K, et al. Lung cancer in patients with severe idiopathic pulmonary fibrosis: critical aspects. In Vivo. 2017;31(4):773–777.
   PubMed Web of Science ®Google Scholar
• Tzouvelekis A, Spagnolo P, Bonella F, et al. Patients with IPF and lung cancer: diagnosis and management. Lancet Respir Med. 2018;6(2):86–88.
   PubMed Web of Science ®Google Scholar
• Colman R, Singer LG, Barua R, et al. Outcomes of lung transplant candidates referred for co-management by palliative care: a retrospective case series. Palliat Med. 2015;29(5):429–435.
   PubMed Web of Science ®Google Scholar
• Leuschner G, Stocker F, Veit T, et al. Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy. J Heart Lung Transplant. 2018;37(2):268–274.
   Google Scholar
• Kistler KD, Nalysnyk L, Rotella P, et al. Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. BMC Pulm Med. 2014;14:139.
   PubMed Web of Science ®Google Scholar
• Thabut G, Mal H, Castier Y, et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg. 2003;126(2):469–475.
   PubMed Web of Science ®Google Scholar
• Lanken PN, Terry PB, Delisser HM, et al. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med. 2008;177(8):912–927.
   PubMed Web of Science ®Google Scholar
• Kalluri M, Richman-Eisenstat J. Breathing is not an option; dyspnea is. J Palliat Care. 2014;30(3):188.
   PubMed Web of Science ®Google Scholar
• Kalluri M, Richman-Eisenstat J. Early and integrated palliative care to achieve a home death in idiopathic pulmonary fibrosis. J Pain Symptom Manage. 2017;53(6):1111–1115.
   PubMed Web of Science ®Google Scholar
• Moore BB, Moore TA. Viruses in idiopathic pulmonary fibrosis. Etiology and exacerbation. Ann Am Thorac Soc. 2015;12(Suppl 2):S186–92.
   PubMedGoogle Scholar
• Public Health Agency of Canada. Canadian immunization guide. Ottawa, Canada: 2018. (update): https://www.canada.ca/en/public-health/services/canadian-immunization-guide.html. Accessed February 11, 2019.
   Google Scholar
• Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63(37):822–825.
   PubMed Web of Science ®Google Scholar
• Swigris JJ, Brown KK, Make BJ, et al. Pulmonary rehabilitation in idiopathic pulmonary fibrosis: a call for continued investigation. Respir Med. 2008;102(12):1675–1680.
   PubMed Web of Science ®Google Scholar
• Dowman L, Hill CJ, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. 2014;10:CD006322.
   PubMed Web of Science ®Google Scholar
• Dowman LM, McDonald CF, Bozinovski S, et al. Greater endurance capacity and improved dyspnoea with acute oxygen supplementation in idiopathic pulmonary fibrosis patients without resting hypoxaemia. Respirology. 2017;22(5):957–964.
   PubMed Web of Science ®Google Scholar
• Cheng L, Tan B, Yin Y, et al. Short- and long-term effects of pulmonary rehabilitation for idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Clin Rehabil. 2018;32(10):1299–1307.
   PubMed Web of Science ®Google Scholar
• Perez-Bogerd S, Wuyts W, Barbier V, et al. Short and long-term effects of pulmonary rehabilitation in interstitial lung diseases: a randomised controlled trial. Respir Res. 2018;19(1): 182.
   PubMedGoogle Scholar
• Vainshelboim B, Fox BD, Oliveira J, et al. Exercise training in idiopathic pulmonary fibrosis. Expert Rev Respir Med. 2016;10(1):69–77.
   PubMed Web of Science ®Google Scholar
• Visca D, Mori L, Tsipouri V, et al. Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respir Med. 2018;6(10):759–770.
   PubMed Web of Science ®Google Scholar
• Jacobs SS, Lindell KO, Collins EG, et al. Patient perceptions of the adequacy of supplemental oxygen therapy. results of the American Thoracic Society nursing assembly oxygen working group survey. Ann Am Thorac Soc. 2018;15(1):24–32.
   PubMed Web of Science ®Google Scholar
• Campbell CD, Smyth MW, Brown L, et al. Air travel for subjects receiving long-term oxygen therapy. Respir Care. 2018;63(3):326–331.
   PubMed Web of Science ®Google Scholar
• Ahmedzai S, Balfour-Lynn IM, Bewick T, et al. Managing passengers with stable respiratory disease planning air travel: British Thoracic Society recommendations. Thorax. 2011;66(Suppl 1):i1–i30.
   PubMedGoogle Scholar
• Cramer D, Ward S, Geddes D. Assessment of oxygen supplementation during air travel. Thorax. 1996;51(2):202–203.
   PubMed Web of Science ®Google Scholar
• Anderson F, Downing GM, Hill J, et al. Palliative performance scale (PPS): a new tool. J Palliat Care. 1996;12(1):5–11.
   PubMed Web of Science ®Google Scholar
• Lee JS, McLaughlin S, Collard HR. Comprehensive care of the patient with idiopathic pulmonary fibrosis. Curr Opin Pulm Med. 2011;17(5):348–354.
   PubMed Web of Science ®Google Scholar
• Kreuter M, Bendstrup E, Russell AM, et al. Palliative care in interstitial lung disease: living well. Lancet Respir Med. 2017;5(12):968–980.
   PubMed Web of Science ®Google Scholar
• Birring SS, Kavanagh JE, Irwin RS, et al. Treatment of interstitial lung disease associated cough: CHEST guideline and expert panel report. Chest. 2018;154(4):904–917.
   Web of Science ®Google Scholar
• Nava S, Rubini F. Lung and chest wall mechanics in ventilated patients with end stage idiopathic pulmonary fibrosis. Thorax. 1999;54(5):390–395.
   PubMed Web of Science ®Google Scholar
• Richeldi L. Time for prevention of idiopathic pulmonary fibrosis exacerbation. Ann Am Thorac Soc. 2015;12(Suppl 2):S181–S185.
   PubMedGoogle Scholar
• Winterbottom CJ, Shah RJ, Patterson KC, et al. Exposure to ambient particulate matter is associated with accelerated functional decline in idiopathic pulmonary fibrosis. Chest. 2018;153(5):1221–1228.
   PubMed Web of Science ®Google Scholar
• Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968–1977.
   PubMed Web of Science ®Google Scholar
• Papiris SA, Kagouridis K, Kolilekas L, et al. Survival in idiopathic pulmonary fibrosis acute exacerbations: the non-steroid approach. BMC Pulm Med. 2015;15: 162.
   PubMed Web of Science ®Google Scholar
• Papiris SA, Kagouridis K, Kolilekas L, et al. Idiopathic pulmonary fibrosis acute exacerbations: where are we now? Expert Rev Respir Med. 2014;8(3):271–273.
   PubMed Web of Science ®Google Scholar
• Ryerson CJ, Cottin V, Brown KK, et al. Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. Eur Respir J. 2015;46(2):512–520.
   PubMed Web of Science ®Google Scholar
• Arcadu A, Moua T. Bronchoscopy assessment of acute respiratory failure in interstitial lung disease. Respirology. 2017;22(2):352–359.
   PubMed Web of Science ®Google Scholar
• Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372(23):2185–2196.
   PubMed Web of Science ®Google Scholar
• Nouha A, Walid F, Rim M, et al. Assessment of nutritional status in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2016;48:PA3703.
   Google Scholar
• Nguyen L, Morello Gearhart A, Cavallazzi R, et al. Nutrition therapy in end-stage lung disease. Curr Nutr Rep. 2017;6(3):291–298.
   Google Scholar